These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. POLE exonuclease domain mutations in endometrial carcinoma: a case report. Pasciuto MP; Felicioni L; Zampacorta C; Ferro B; Di Marino P; Primavera FC; Lucidi A; Rossetti R; Barbareschi M; Marchetti A; Buttitta F; D'Angelo E Pathologica; 2023 May; 1(1):181-185. PubMed ID: 37216304 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778 [TBL] [Abstract][Full Text] [Related]
5. Fast and reliable Sanger POLE sequencing protocol in FFPE tissues of endometrial cancer. Laczmanska I; Michalowska D; Jedryka M; Blomka D; Semeniuk M; Czykalko E; Abrahamowska M; Mlynarczykowska P; Chrusciel A; Pawlak I; Maciejczyk A Pathol Res Pract; 2023 Feb; 242():154315. PubMed ID: 36738508 [TBL] [Abstract][Full Text] [Related]
6. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing. Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426 [TBL] [Abstract][Full Text] [Related]
7. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study. Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887 [TBL] [Abstract][Full Text] [Related]
10. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features. Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522 [TBL] [Abstract][Full Text] [Related]
11. Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity. Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550 [TBL] [Abstract][Full Text] [Related]
12. A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report. Cui J; Chen X; Zhai Q; Chen N; Li X; Zhang Y; Wang H; Bian X; Gao N; Chen D; Chen Z; Zhang S; Chen Y Diagn Pathol; 2023 Feb; 18(1):19. PubMed ID: 36765365 [TBL] [Abstract][Full Text] [Related]
13. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557 [TBL] [Abstract][Full Text] [Related]
14. Van den Heerik ASVM; Ter Haar NT; Vermij L; Jobsen JJ; Brinkhuis M; Roothaan SM; Leon-Castillo A; Ortoft G; Hogdall E; Hogdall C; Van Wezel T; Lutgens LCHW; Haverkort MAD; Khattra J; McAlpine JN; Creutzberg CL; Smit VTHBM; Gilks CB; Horeweg N; Bosse T JCO Glob Oncol; 2023 May; 9():e2200384. PubMed ID: 37229628 [TBL] [Abstract][Full Text] [Related]
15. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis. Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130 [TBL] [Abstract][Full Text] [Related]
16. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas. Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464 [TBL] [Abstract][Full Text] [Related]
18. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma. Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219 [TBL] [Abstract][Full Text] [Related]
19. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations. Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482 [TBL] [Abstract][Full Text] [Related]
20. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]